Autolus Therapeutics' (AUTL) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL - Free Report) in a research note released on Monday,Benzinga reports. Needham & Company LLC currently has a $10.00 price target on the stock.

Several other brokerages have also issued reports on AUTL. Redburn Atlantic upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Trading Down 2.5 %

Shares of AUTL traded down $0.06 on Monday, reaching $2.30. 950,932 shares of the company's stock traded hands, compared to its average volume of 1,135,189. The stock's 50 day simple moving average is $2.83 and its two-hundred day simple moving average is $3.60. The stock has a market cap of $612.02 million, a PE ratio of -1.90 and a beta of 2.05. Autolus Therapeutics has a 52-week low of $2.07 and a 52-week high of $7.37.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company earned ($0.26) EPS. Analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. ProShare Advisors LLC bought a new stake in Autolus Therapeutics during the second quarter valued at approximately $43,000. Capstone Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter worth $51,000. Daiwa Securities Group Inc. grew its position in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after acquiring an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new position in Autolus Therapeutics in the third quarter worth $91,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock valued at $139,000 after acquiring an additional 14,959 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.